NOVARTIS for NOVARTIS
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
2025 Appropriations Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act FY 2025 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Federal Budget Reconciliation 2026 Appropriations
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| SARAH DURR | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Copyright/Patent/Trademark CPT
S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| SARAH DURR | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Health Issues HCR
340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program Accelerated Approval Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues H.R.946: ORPHAN Cures Act H.R. 1262: Give Kids a Chance Act of 2025 S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| SARAH DURR | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Medicare/Medicaid MMM
H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| SARAH DURR | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Taxation/Internal Revenue Code TAX
Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms Tax Relief for American Families and Workers Act Foreign Direct Investment Expensing of R&D Expenditures H.R. 2425 - Unfair Tax Prevention Act of 2025 Tax Cuts and Jobs Act, PL 115-97
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| SARAH DURR | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
| THOMAS ANDREW SUTER New | — |
Trade (domestic/foreign) TRD
Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| SARAH DURR | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Labor Issues/Antitrust/Workplace LBR
Anti-Trust Reform
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH DURR | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.